State coverage
Iowa
Medicaid, for obesity: Covers with conditions. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- Wegovy and Zepbound are Preferred on the drug list, but its own footnote excludes the weight-loss indication.
- Appeal deadline
- 90 days from the date on the notice of decision if your Medicaid is fee-for-service; 120 days from your health plan's own appeal decision if you are in managed care source
- Date read
- September 2026
Iowa Medicaid's pharmacy benefit runs off one statewide Preferred Drug List, and on first read it looks generous: Wegovy and Zepbound both sit in the Endocrine Metabolic Agents class as Preferred brand drugs, with no non-preferred detour required. Read the footnote attached to both, though, and the generosity narrows fast — it exists to route the drugs toward specific FDA-approved uses, and weight loss is not among them.
The document that does the routing is a dedicated prior-authorization form for incretin mimetics prescribed outside a diabetes diagnosis. It opens by naming the thing it will not pay for, then lays out three doors that are not that: reducing cardiovascular risk in a patient with established heart disease, treating obstructive sleep apnea, and treating a liver condition called MASH. Each door has its own BMI floor, its own specialist-involvement requirement, and its own maintenance-dose ceiling.
A second, separate class handles the same molecules prescribed for type 2 diabetes — Ozempic, Rybelsus, Trulicity, Victoza and the rest — under an ordinary metformin-trial-first structure. Wegovy and Zepbound do not appear in that class at all; Iowa keeps the diabetes and non-diabetes uses of these drugs on entirely separate prior-authorization tracks.
The state's own pharmacy provider manual states the underlying rule in the plainest terms available: Medicaid does not pay for drugs used to cause weight loss. That line predates the GLP-1s by years and traces back to the same federal Medicaid carve-out most states rely on. Iowa's newer form does not repeal it — it built two or three narrow, medically specific doors through it.
What we could verify for Iowa
The state's drug list carries an Endocrine Metabolic Agents class and places the newer drugs in it as Preferred, each flagged with the same comment. The list defines Comment 12 as: "PA Required. Weight loss indication not covered." Both Wegovy and Zepbound are listed as Brand, Preferred, Comment 12.
Iowa Department of Health and Human Services, Iowa Medicaid Preferred Drug List, effective January 2026 · source
The state's non-diabetes prior authorization form opens with the exclusion, not the exception: "Prior authorization (PA) is required for incretin mimetics not otherwise covered by the Anti-Diabetics Non-Insulin Agents PA criteria for covered FDA approved for compendia indications. Payment for excluded medical use(s) (e.g. weight loss), as defined in the Iowa State Plan and Iowa Administrative Code 441 – 78.2(4) will be denied." What follows are three qualifying uses: reducing the risk of "major adverse cardiovascular events (MACE)" in a patient with established cardiovascular disease and a BMI of 27 or higher (Wegovy only); moderate-to-severe obstructive sleep apnea with a BMI of 30 or higher and a documented apnea-hypopnea index of 15 or more (Zepbound only); and "noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)" with confirmed liver fibrosis (Wegovy only).
Iowa Department of Health and Human Services, Request for Prior Authorization — Incretin Mimetics for Non-Diabetes Indications (Form 470-0058), effective January 2026 · source
The pharmacy provider manual's list of drugs excluded from coverage opens with this line: "Medicaid payment will not be made for: Drugs used to cause anorexia, weight gain or weight loss." The same manual separately lists "GLP-1 Agonist/Basal Insulin Combinations" among the drug classes that carry their own prior-authorization criteria for diabetes use. The chapter is stamped "Revised October 21, 2022" on every page and is still the version hosted at hhs.iowa.gov.
Iowa Department of Health and Human Services, Providers' Manual — Prescribed Drugs, Chapter III, effective October 2022 · source
A second, older prior authorization criteria document — covering the ordinary diabetes-indicated class rather than the non-diabetes carve-out — states the same rule for that class in one sentence: "Requests for weight loss are not a covered diagnosis of use and will be denied." That line sits directly under the criteria for "Anti-Diabetics, Non-Insulin Agents," the class that includes the diabetes-indicated GLP-1s.
Iowa Department of Health and Human Services, Iowa Medicaid Drug Prior Authorization Criteria, effective July 2024 · source
Iowa's appeals overview states two different clocks depending on the path. For a standard fee-for-service Medicaid appeal: "the appellant must file the appeal before the 90th day following the date on the NOD [Notice of Decision]." For a managed-care member who has already gone through the plan's own appeal: "A hearing will be held if the state fair hearing appeal request is made within 120 calendar days of the date on the MCO appeal determination."
Iowa Department of Health and Human Services, Administrative Rules and Appeals Bureau, Appeals Process Overview · source
Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.
If the appeal fails, or you cannot wait
Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| CoreAge RxCheck availability | Advertises $99 a month for compounded semaglutide, flat across doses. Read the terms before you sign up: the lander our link opens has shown $149 rather than $99, and a consultation fee can be charged on top and may not be refundable. |
| OakCheck availability | Flat price across doses, free shipping with supplies. |
| Care Bare RxCheck availability | Names its pharmacies with addresses; sells brand Ozempic as well as compounded. |
| Gala HealthCheck availability | All doses one price, but the advertised rate needs a yearly subscription. |
| Synergy RxCheck availability | Providers licensed in your state; publishes no GLP-1 price before the consult. |
| Breeze MedsCheck availability | Serves all 50 states; publishes a starting price only. |
| Direct MedsCheck availability | No monthly membership, and one price at every dose. The lander our link opens starts at $147 and reads its own discount two ways on the same screen: the banner across the top says $150 off, the product tiles below it say up to $200 off. |
| FoundCheck availability | Bills the clinical visits through insurance where it is in network, with the medication charged separately. Read its Medicare Part D route closely: it advertises brand GLP-1s from $50 a month, and the footnote under that offer says the $50 does not count toward your Part D deductible or out-of-pocket maximum, and that Extra Help does not apply. |
| EdenCheck availability | Two different prices for the same drug depending on which door you come in. The lander our link opens advertises $99 a month for semaglutide, held at every dose, with no membership fee. Eden's own weight-loss page, read the same day, offers it from $99 a month plus an Eden Membership, and the footnote there says the membership is $39 the first month and $99 after, and that medication is not available without one. |
| ShedRxCheck availability | Publishes no price before the questionnaire: you answer it, pick a plan and see the cost at checkout. Sells injections plus needle-free drops and lozenges, and a footnote on the same page names sixteen states where the oral forms are not available. |
| TrimiCheck availability | Compounded tirzepatide at $125 a month and semaglutide at $99, each on the annual plan and each the same price at every dose. One membership covers the medication, the clinician visits and shipping. |
| He & She MDCheck availability | Advertises semaglutide from $99 a month and charges only if a prescription is written. The printed tiers are higher than the headline: $139 a month on six months, billed $834 at once, and $149 a month on three. GLP-1s ship to every state except Louisiana. |
| HealthRXCheck availability | Compounded semaglutide from $133 a month on a three-month plan and as low as $99 on twelve; tirzepatide from $209, as low as $179. ⚠ The page states its member reviews are illustrative composites rather than real patients. |
| Pallas HealthCheck availability | Compounded semaglutide at $139 for the first month and then $597 every twelve weeks, and tirzepatide at $179 then $897. ⚠ The page discloses that some of its content is AI-generated and that its imagery uses models rather than patients. |
| MEDGmCheck availability | GLP-1 injections from $179 and tablets from $249, with brand-name options priced as a membership plus the cost of the drug — $99 for Zepbound or Wegovy, $171 for Ozempic. ⚠ It discloses AI-generated content and actor imagery beside more than twenty named patient testimonials. |
| Bodybuilding Health+Check availability | Compounded tirzepatide runs $174.67 to $209 a month depending how many months are bought at once, and semaglutide is tiered the same way. ⚠ The program is listed as Bodybuilding.com; the page this link opens brands itself Bodybuilding Health+ and is operated by Dynamo Group LLC. |
| Strut HealthCheck availability | A multi-category telehealth storefront — sexual health, testosterone, hair, skin, peptides, menopause — where weight loss is one tile among six. It publishes no price for a GLP-1, or for anything else, on the page this link opens. |
| RxSpan MDCheck availability | Multi-category telehealth that promises transparent pricing and no hidden fees, and then publishes no price at all — not for a GLP-1 and not for any other product — on the page this link opens. |
Prices in those notes were read from each company's own site in August 2026 and September 2026, and they change often. Check the current number before you buy.
Where this comes from
- Iowa Department of Health and Human Services, Iowa Medicaid Preferred Drug List, effective January 2026 — www.iowamedicaidpdl.com/content/dam/ffs-medicaid/ia/iowa-webpdl-10126.pd
- Iowa Department of Health and Human Services, Request for Prior Authorization — Incretin Mimetics for Non-Diabetes Indications (Form 470-0058), effective January 2026 — www.iowamedicaidpdl.com/content/dam/ffs-medicaid/ia/incretin-mimetics-no
- Iowa Department of Health and Human Services, Providers' Manual — Prescribed Drugs, Chapter III, effective October 2022 — hhs.iowa.gov/media/7769/download?inline=
- Iowa Department of Health and Human Services, Iowa Medicaid Drug Prior Authorization Criteria, effective July 2024 — hhs.iowa.gov/media/13645/download?inline=
- Iowa Department of Health and Human Services, Administrative Rules and Appeals Bureau, Appeals Process Overview — hhs.iowa.gov/media/607/download
Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.